Research Article

P21-Activated Protein Kinase Is Overexpressed in Hepatocellular Carcinoma and Enhances Cancer Metastasis Involving c-Jun NH_2-Terminal Kinase Activation and Paxillin Phosphorylation

Yick-Pang Ching,[1] Veronica Y.L. Leong,[1] Man-Fong Lee,[1] Hai-Tao Xu,[1] Dong-Yan Jin,[2] and Irene Oi-Lin Ng[1]

Departments of [1]Pathology and [2]Biochemistry, S.H. Ho Foundation Research Laboratories and Hong Kong Jockey Club Clinical Research Centre, LKS Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong

Abstract

Hepatocellular carcinoma (HCC) is one of the major malignancies in the world. The prognosis of HCC is poor, due to frequent intrahepatic metastasis and tumor recurrence. P21-activated protein kinase (Pak1), a main downstream effector of small Rho GTPases, Rac1 and Cdc42, plays an important role in the regulation of cell morphogenesis, motility, mitosis, and angiogenesis. Here, we show that *Pak1* gene was overexpressed in human HCCs. Overexpression of Pak1 in human HCCs was associated with more aggressive tumor behavior in terms of more metastatic phenotype and more advanced tumor stages. In addition, HCC cell line stably expressing Pak1 displayed increased cell motility rates and, conversely, knockdown of endogenous Pak1 expression by small interfering RNA reduced the migration rates of HCC cells. In an established metastatic HCC cell line, we found that Pak1 was overexpressed compared with its primary HCC cell line and this overexpression was associated with higher cell motility. Importantly, we found that c-Jun NH_2-terminal kinase (JNK) was activated in HCC cell lines overexpressing Pak1. Inhibition of the JNK activity by chemical inhibitor significantly reduced the migration rates of HCC cells via attenuation of paxillin phosphorylation at Ser^{178}. In conclusion, our results document that Pak1 is overexpressed in HCCs and plays an important role in the metastasis of HCC. The mechanism by which Pak1 induces cancer metastasis may involve activation of JNK and phosphorylation of paxillin. [Cancer Res 2007;67(8):3601–8]

Introduction

Hepatocellular carcinoma (HCC) is a major malignancy worldwide (1) and has high incidences of tumor recurrence and metastasis. Despite improvements in treatment results, the overall prognosis of HCC is still unsatisfactory.

P21-activated protein kinase 1 (Pak1) is a main downstream effector of small Rho GTPases Rac1 and Cdc42 and plays an important role in the regulation of cell morphogenesis, motility, survival, mitosis, and angiogenesis (2, 3). Amplification of *Pak1* has been found in several human cancers, including colorectal and breast cancer (4, 5). In addition, emerging evidence has suggested that Pak1 is required for progression and metastasis of breast cancer by mediating growth factor-induced motility and invasiveness (6, 7). More recently, Pak1 expression has been shown to significantly increase in colorectal cancer metastasis to lymph nodes (5). These results suggest that Pak1 is potentially important in carcinogenesis and cancer metastasis.

The molecular mechanism by which Pak1 contributes to carcinogenesis is unclear. Pak1 is believed to be involved in several cell signaling pathways. For instance, activation of Pak1 and its downstream signaling pathways, such as mitogen-activated protein kinases (MAPK) and nuclear factor-κB (NF-κB), are believed to be important in carcinogenesis (8). Activation of Pak1 not only activates the NF-κB cell survival pathway but also inhibits apoptosis via phosphorylation of the proapoptotic protein Bad, thereby providing a growth advantage to tumor cells (9, 10). In addition, expression of dominant-inactive form of Pak1 in Rat1 fibroblasts can block Ras-induced cell transformation, indicating that Pak1 plays a role in cell transformation and Ras signaling (11). Furthermore, expression of dominant-active form of Pak1 in breast cancer cells induces the expression of vascular endothelial growth factor, suggesting that Pak1 is also involved in angiogenesis (12).

The role of Pak1 in hepatocarcinogenesis has never been explored. In this study, we sought to examine the expression of Pak1 in human HCCs and characterize its roles in HCC. Our data indicate that Pak1 expression was significantly up-regulated in human HCCs. This overexpression was associated with more aggressive tumor behavior. Pak1 also enhanced the motility of HCC cells as well as the phosphorylation of c-Jun NH_2-terminal kinase (JNK) and paxillin. Our findings define a novel Pak1/JNK/paxillin pathway critically involved in the metastasis of HCC.

Materials and Methods

Materials. Anti-Pak1, anti–phospho-Pak1, anti-JNK, anti–phospho-JNK, anti-p42/44MAPK, anti–phospho-MAPK, anti-Akt, and anti–phospho-Akt antibodies were obtained from Cell Signaling Technology (Beverly, MA). Mouse anti-Rac1 and anti-Cdc42 antibodies were from BD Biosciences (Palo Alto, CA) and anti-paxillin antibody was from Upstate (Charlottesville, VA). Rabbit anti–green fluorescent protein (GFP) and anti-actin antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA). Anti–phospho-S178 paxillin antibody was from Abcam (Cambridge, United Kingdom). Chemicals were purchased from Sigma (St. Louis, MO) unless otherwise stated.

Plasmids. The Pak1 construct, pCMV6-Pak1, was a generous gift from Dr. Gary Bokoch (The Scripps Research Institute, La Jolla, CA). Plasmid pEGFP-Pak1 was constructed by subcloning a *Bam*HI/*Eco*RI fragment containing full-length cDNA of Pak1 into pEGFP vector (Clontech, Palo Alto, CA) via the *Bgl*II/*Eco*RI sites. The Pak1 dominant-inactive mutant was constructed by mutating the lysine at residue 299 to arginine (pEGFP-Pak1

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Requests for reprints: Yick-Pang Ching, Department of Pathology, The University of Hong Kong, Room L7-04, Laboratory Block, Faculty of Medicine Building, Pokfulam, Hong Kong. Phone: 852-2819-9656; Fax: 852-2819-5375; E-mail: ypching@hkucc.hku.hk or Irene Oi-Lin Ng, Department of Pathology, The University of Hong Kong, Queen Mary Hospital, Room 127B, University Pathology Building, Pokfulam, Hong Kong. Phone: 852-2855-3967; Fax: 852-2872-5197; E-mail iolng@hku.hk.

©2007 American Association for Cancer Research.

doi:10.1158/0008-5472.CAN-06-3994

Downloaded from cancerres.aacrjournals.org on December 5, 2020. © 2007 American Association for Cancer Research.



Figure 1. Overexpression of Pak1 in primary HCCs. *A, box plot,* quantitative real-time RT-PCR results of HCCs and corresponding nontumorous samples. **, $P < 0.001$, *t* test. *B, top,* representative results of Western blot analysis of HCC (*T*), nontumorous tissue (*NT*), and normal liver tissue sample (*NL*); *bottom,* relative expression (*T/NT*) of Pak1 after quantification by scanning. *C, left,* representative immunohistochemical cytoplasmic and membranous staining of HCC (*T*) and nontumorous liver (*NT*); *right,* quantification of immunohistochemical results of 29 HCC cases showing underexpression (*T<NT*), normal (*NT=T*), and overexpression (*T>NT*) of membranous and cytoplasmic staining of Pak1.

K299R) using the QuikChange Site-Directed Mutagenesis kit (Stratagene, La Jolla, CA) as per protocol suggested by manufacturer. The mutagenic primer sequence was 5′-GTGGCCATTAGGCAGATGAATCTTC.

Tissue culture and stable clone selection. HepG2 (American Type Culture Collection, Manassas, VA), H2M, and H2P cells (generous gifts from Dr. X.Y. Guan, Department of Clinical Oncology, University of Hong Kong, Pokfulam, Hong Kong; ref. 13) were maintained in DMEM supplemented with 10% fetal bovine serum (JRH Biosciences, Lenexa, KS) and 100 units each of penicillin and streptomycin. Cells were transfected with 3 μg DNA constructs using LipofectAMINE 2000 reagent (Invitrogen, Carlsbad, CA) as per protocols recommended by the manufacturer. For RNA interference (RNAi) of Pak1, 150 pmol each of Pak1 small interfering RNA (siPak1) and control siRNA (both from Cell Signalling Technology) and siPak1-2 (sense sequence 5′-CCUAAAC-CAUGGUUCUAAA; First Base Pte Ltd., Singapore) were used for each transfection using LipofectAMINE 2000 reagent. For constructing the stable transfectant, pEGFP and pEGFP-Pak1 wild-type (WT) were separately transfected into HepG2. Forty-eight hours after transfection, G418 at 0.8 mg/mL (Calbiochem, La Jolla, CA) was added for the selection of stable clones.

Reverse transcription-PCR. Total RNA was extracted from tumors and their corresponding nontumorous liver samples from HCC patients using the Trizol reagent (Life Technologies, Inc., Grand Island, NY), and 2 μg each RNA sample was used to prepare cDNA. The semiquantitative PCR primer sequences for Pak1 were 5′-CGTGGCTACATCTCCCATTT (forward) and 5′-TC-CCTCATGACCAGGATCTC (reverse). Quantitative real-time PCR was done using the Applied Biosystems Taqman system (Foster City, CA; Pak1 probe, 5′-AAAGAGCTGCTACAGCATCAATTCC). Cellular 18S mRNA was used as an internal control.

Confocal microscopy. Cells were fixed in 4% paraformaldehyde for 15 min, washed, and permeabilized with 0.2% Triton in PBS for 15 min. Slides were stained for 10 min with TRITC-phalloidin (Invitrogen) at room temperature and immunofluorescence imaging was captured in a Zeiss LSM510 laser scanning confocal microscope (Carl Zeiss Microimaging Inc., Thornwood. NY).

Western blot analysis. Human tissue samples and HCC cells were harvested into radioimmunoprecipitation assay lysis buffer [50 mmol/L Tris-HCL (pH 7.4), 1% NP40, 0.25% sodium deoxycholate, 150 mmol/L NaCl, 1 mmol/L EDTA, 5 mmol/L sodium fluoride, 1 mmol/L DTT] with freshly added protease inhibitor cocktail (1 mmol/L phenylmethylsulfonyl fluoride, 1 μg/mL leupeptin, 2 μg/mL aprotinin, and 2 μg/mL soybean trypsin inhibitor). The cell lysate was cleared by centrifugation at 4°C and the supernatant was stored in small aliquots at −80°C. Normally, 20 μg sample was loaded into each lane, separated by SDS-PAGE, transferred to polyvinylidene difluoride membrane, and probed with respective antibodies.

Transwell cell migration, wound healing, and proliferation assay. The methods for Transwell cell migration, wound healing, and proliferation assay were described previously (14). The best fit curve of growth doubling time for proliferation assay was calculated using GraphPad prism software (GraphPad Software, Inc., San Diego, CA).

Cell spreading assay. Stably transfected cells (1×10^5) were seeded in triplicates onto a 12-well plate that had been coated with fibronectin (Calbiochem) at 10 μg/mL for 1 h at room temperature and washed with PBS. Cells were allowed to attach onto the plate. Unattached cells were washed away with PBS and attached cells were trypsinized and counted at different time intervals.

Immunohistochemistry. The method for immunohistochemical staining was described previously (15). Briefly, formalin-fixed paraffin sections were stained for Pak1 and phospho-paxillin (1:500 and 1:1,000 dilutions, respectively) using the streptavidin-biotin immunoperoxidase technique.

Downloaded from cancerres.aacrjournals.org on December 5, 2020. © 2007 American Association for Cancer Research.

Antigen retrieval was achieved by microwave treatment with citrate buffer at pH 6.0 at 95°C for 9 min. The immunohistochemical staining was scored in the following grades according to the percentage of positive hepatocytes: 0, <10% positive; 1, 10% to 30% positive; 2, 31% to 75% positive; and 3, >75% positive.

Clinical HCC samples and patients. Paired samples of primary HCCs and the corresponding nontumorous liver tissues from Chinese patients were collected at the time of surgical resection at The University of Hong Kong, Queen Mary Hospital (Pokfulam, Hong Kong). All specimens were obtained immediately after surgical resection, snap frozen in liquid nitrogen, and kept at −70°C. The diagnosis of recurrence was based on typical imaging findings on computerized tomographic scan or arteriography, and if necessary, percutaneous fine-needle aspiration cytology. Disease-free survival was measured from the date of hepatic resection to the date when recurrent disease was diagnosed or, in the absence of detectable tumor, to the date of death or last follow-up. Overall survival was measured from the date of hepatic resection to the date of death or last follow-up.

Statistical analysis. Fisher's exact or χ^2 test was used for statistical analysis of categorical data, whereas independent t test was used for continuous data. Tests were considered significant when their P values were <0.05.

Results

Pak1 was overexpressed in human HCCs. To determine if Pak1 transcript was overexpressed in HCC, paired samples of tumor and their corresponding nontumorous tissues were analyzed using real-time quantitative reverse transcription-PCR (RT-PCR). After normalization with 18S RNA control, 75% (27 of 36) of the HCC samples were found to have a higher expression of Pak1 transcript (>2-folds) in the tumors compared with their corresponding nontumorous livers. Overall, the Pak1 expression in the tumor samples was significantly higher than that in the nontumorous livers (P < 0.001; Fig. 1*A*).

To confirm the overexpression of Pak1 in HCCs at protein level, Western blot analysis was done in six pairs of HCC samples with overexpression of Pak1 mRNA (Fig. 1*B*). An increased level of Pak1 protein was observed in the tumor tissues compared with the corresponding nontumorous livers. The protein loading was normalized with β-actin control, and a normal liver tissue sample was included for comparison.

To further confirm the up-regulation and evaluate the localization of Pak1 in HCCs, immunohistochemical staining was done on 29 randomly selected HCC samples using the anti-Pak1 antibody and their immunoreactivity was scored. Positive staining was observed in both nontumorous hepatocytes and HCC cells. However, significantly stronger staining of Pak1 was observed in HCCs than in the nontumorous liver tissues (Fig. 1*C*). Interestingly, both membranous and cytoplasmic patterns of staining were observed in HCCs, whereas only membranous pattern of staining was observed in nontumorous hepatocytes (Fig. 1*C*). Taken together, these data confirm that Pak1 was overexpressed in human HCCs.

Clinicopathologic correlation of Pak1 overexpression. To understand the clinicopathologic significance of Pak1, we correlated the overexpression of Pak1 mRNA with the clinicopathologic features of the patients. Pak1 mRNA overexpression was significantly associated with the presence of venous invasion (P = 0.022), poorer cellular differentiation by Edmondson's grading (P < 0.001; ref. 16), more advanced tumor stages (P = 0.003), and shorter disease-free survival (P = 0.022; Table 1).

Overexpression of Pak1 enhanced cell migration and cell spreading. To characterize the effects of Pak1 in HCC, we used HepG2 hepatoma cells to establish stable cell lines overexpressing the enhanced GFP (EGFP) fusion form of Pak1. Ectopic expression of Pak1 in the stably transfected cells (WT-5 and WT-7) was confirmed by anti-GFP antibodies (Fig. 2*A*). To test whether Pak1 affects the motility of HCC cells, Transwell experiment was done on HepG2 and HepG2/Pak1 clones (WT-5 and WT-7). We observed that Pak1 stable clones WT-5 and WT-7 migrated faster than the parental cells by about 3- and 2-folds, respectively, under the stimulation of growth factor present in the complete growth medium (Fig. 2*A*).

In wound healing assay in the absence or presence of a cell division inhibitor, mitomycin C, both stable clones were able to close the wound in 24-h time, significantly faster than the parental cells (Fig. 2*B*). Similar result was obtained with cells pretreated with mitomycin C (data not shown). Thus, we observed that Pak1 overexpression in HCC cells increased cell migration rate.

Table 1. Association of overexpression of Pak1 mRNA with clinicopathologic features in human HCCs

Clinicopathologic features		Pak1 expression		
		Not overexpressed	Overexpressed	P
Venous invasion	Absent	8	7	0.002
	Present	1	18	
Tumor microsatellite	Absent	9	17	0.209
	Present	4	19	
Liver invasion	Absent	10	17	0.086
	Present	2	17	
Cellular differentiation (Edmondson's grading)	I–II	8	4	<0.001
	III–V	1	19	
Tumor size (cm)	≤5	5	6	0.123
	>5	4	17	
Tumor stage	I–II	7	4	0.003
	III–V	2	18	
Tumor encapsulation	Absent	7	25	0.331
	Present	6	11	
Disease-free survival (mo)	Median	Not reached	6.5 ± 6.4	0.022
	Mean	43.1 ± 7.7	18.3 ± 4.2	
Overall survival (mo)	Median	Not reached	29.8 ± 12.6	0.063
	Mean	49.2 ± 5.9	30.8 ± 4.9	

Downloaded from cancerres.aacrjournals.org on December 5, 2020. © 2007 American Association for Cancer Research.



Figure 2. Pak1 overexpression promoted cell migration. *A,* Transwell assay done on EGFP control, WT-5, and WT-7 cells. *Top,* representative images show the numbers of cells having migrated to the lower chamber. *Bottom,* quantification of three independent experiments. *Columns,* mean; *bars,* SD. *, $P < 0.01$, *t* test. *Inset,* expression of GFP-Pak1 in stable clones detected by anti-GFP antibody. *B,* wound healing assay. Size of the wound at time 0 and 24 h for EGFP control, WT-5, and WT-7 cells. *C,* cell adhesion assay done for WT-5, WT-7, and EGFP control. *D,* the WT-5 and EGFP control cells were serum starved and stimulated with LPA for 15 min. The representative confocal images show the staining of stress fiber using TRITC-phalloidin (*Phalloidin*) and focal adhesion complex using anti-paxillin (*Paxillin*) antibody.

To address the mechanism by which Pak1 enhanced migration, we did the cell spreading assay. Cells were allowed to spread onto the fibronectin-coated plate and the number of cells attached against time was determined. We found that the two stable clones required significantly longer time for attachment compared with the EGFP control cells (Fig. 2*C*).

Expression of Pak1 down-regulated stress fiber formation. We tested if Pak1 regulated the actin polymerization to increase the migration rates. The WT-5 stable clone was serum starved and followed by treatment with lysophosphatidic acid (LPA) to stimulate the formation of stress fibers and focal adhesion complexes. As revealed by phalloidin staining, much fewer stress fibers were formed in the WT-5 cells compared with the control (Fig. 2*D*). The focal adhesion complex was fewer, but larger, in the LPA-stimulated WT-5 stable clone than the control. These results suggest that Pak1 enhances migration by down-regulating stress fiber and focal adhesion complex formation.

Knockdown of endogenous Pak1 by siRNA reduced HCC cell migration. To confirm the role of Pak1 on cell migration, we used RNAi to specifically knockdown endogenous Pak1 in HCC cells. The specific knockdown of endogenous Pak1 protein using siRNA in HepG2 cells was confirmed with immunoblotting (Fig. 3*A*). In Transwell assay, HepG2 cells transfected with Pak1 siRNA migrated much more slowly (~50%) than those treated with control siRNA, suggesting that loss of Pak1 retarded the migration of HCC cells (Fig. 3*A*). To further examine if the Pak1 kinase activity was essential for the HCC cell migration, the WT and a dominant-inactive form of Pak1 (Pak1 K299R) were transfected into HepG2 cell for Transwell assay. As compared with the GFP control, the WT form of Pak1 promoted the migration of HepG2 cells, whereas the dominant-inactive form inhibited their migration (Fig. 3*B*).

In addition, we examined Pak1 expression in a pair of primary and its corresponding metastatic HCC cell lines (i.e., H2P and H2M cells, respectively; ref. 13). H2P and H2M cells were derived from a HCC patient with intrahepatic metastasis, and H2P cells were isolated from the primary cancer, whereas H2M cells were isolated from its occlusive tumor venous thrombus. The expression of *Pak1* at both mRNA and protein levels was much higher in H2M than in H2P cells, indicating that Pak1 may play a role in the metastasis of HCC (Fig. 3*C*). To explore if Pak1 regulates the H2M cell migration, we did the Pak1 siRNA knockdown experiment in H2M cells. The knockdown of Pak1 expression with two different siRNAs in the metastatic H2M cells remarkably reduced the migration rate of the cells (Fig. 3*D*).

Overexpression of Pak1 had no effect on the proliferation rate of HCC cells. Overexpression of Pak1 has been reported to increase cell proliferation in breast cancer by up-regulating the expression of cyclin D1 (17). However, the role of Pak1 in the progression of HCC remained elusive. To address if overexpression of Pak1 promoted cell growth, cell proliferation assay was done. The effect of Pak1 on HCC cell proliferation was mild, and the doubling time of Pak1 stable cell lines, WT-5 and WT-7, (~26 h) was only slightly shorter than that of the EGFP control (~30 h; Fig. 4). In addition, we found no significant difference of cyclin D1 expression between the control and Pak1-overexpressing HCC cell lines (Fig. 4).

Phosphorylation of Pak1 and activation of its downstream targets in HCC. To understand how Pak1 induced HCC cell migration, we examined the activity and downstream signaling of Pak1 in human HCCs. Three pairs of human HCC samples with Pak1 overexpression (Fig. 5*A, cases 216, 217*, and *220*) and an HCC with normal expression of Pak1 (Fig. 5*A, case 211*), based on the result of RT-PCR, were randomly selected for the analysis of phosphorylation of Pak1 and its downstream substrates. Pak1, but not its upstream regulators, Cdc42 and Rac1, were overexpressed in all three selected samples. In addition, phosphorylation of Pak1 was obviously increased in human HCCs with Pak1 overexpression compared with the corresponding nontumorous liver tissues, suggesting that the activity of Pak1 may be up-regulated in HCCs (Fig. 5*A*). We observed that one of the well-defined downstream effectors of Pak1

Downloaded from cancerres.aacrjournals.org on December 5, 2020. © 2007 American Association for Cancer Research.

(i.e., the JNK) was phosphorylated in Pak1-overexpressing tumor samples, whereas another MAPK, extracellular signal-regulated kinase (ERK) 1/2, was not (Fig. 5*A*). This result indicates that activation of Pak1 is associated with phosphorylation of JNK in HCCs.

The correlation between overexpression of Pak1 and the activation of JNK in HCC clinical samples prompted us to examine the activation of JNK in HepG2 cells stably expressing Pak1. We found that JNK phosphorylation was considerably increased in WT-5 and WT-7 cells. In contrast, inhibition of JNK activity by a pharmacologic JNK inhibitor, SP600125, significantly reduced the migration rates of the two Pak1 stable clones, but not the control cells, in Transwell assay (Fig. 5*B*). This implies that JNK activity is required for the Pak1-mediated HCC cell migration. To confirm that the JNK activation was required for Pak1-mediated migration of HCC cells, we perform the Transwell assay with H2M cells in the presence of the JNK inhibitor. We observed that the migration of the metastatic H2M cells was specifically inhibited by SP600125, whereas the other MAPK inhibitors, SB203580 for p38 MAPK and U0126 for MEK, had very little or no effect on the migration of H2M cells (Fig. 5*C*).

Phosphorylation of paxillin by JNK is important for HCC cell migration. Recently, Huang et al. (18) reported that direct phosphorylation of paxillin at Ser^{178} by JNK played an important role in the regulation of rat tumor epithelial cells and fish keratocyte movement. In light of this, we hypothesized that overexpression of Pak1 might regulate HCC migration via JNK phosphorylation of paxillin. To test this hypothesis, hepatocyte growth factor (HGF) was used to activate endogenous Pak1 in H2M cells. HGF was chosen because of its potent effect on hepatocyte migration. Pak1 phosphorylation was increased with increasing dosage of HGF in H2M cells, and this was similar for the phosphorylation of JNK and paxillin at S178 (Fig. 6*A*), suggesting that they may regulate in a similar pathway.

Activation of Pak1 in HGF-treated H2M cells is likely to be regulated by activation of Cdc42, but not by Rac1, which had a high basal activity in H2M cells (Supplementary Fig. S1). To further delineate the signaling pathway, we used Pak1 siRNA and JNK inhibitor SP600125 to specifically inhibit the activity of Pak1 and JNK, respectively. Inhibition of JNK activity almost completely abolished the phosphorylation of paxillin S178, whereas knockdown of Pak1 expression substantially reduced JNK and paxillin S178 phosphorylation (Fig. 6*B*).

To confirm the role of S178 paxillin phosphorylation in HCC, we examine our human HCCs with immunohistochemical staining. Our result showed that the expression of S178 paxillin in Pak1-overexpressing human HCCs was substantially increased in the tumor cells, localizing to the nuclei (Fig. 6*C*). Taken together, these findings suggest a novel pathway in which Pak1 induces phosphorylation of JNK, which in turn phosphorylates paxillin at S178, thus promoting HCC cell migration.

Discussion

In this study, we examined the role of Pak1 in HCC. Pak1 was frequently (~75%) and significantly overexpressed in human HCCs. Importantly, Pak1 overexpression significantly correlated with more aggressive tumor behavior in terms of venous invasion, poorer cellular differentiation, more advanced tumor stage, and shorter disease-free survival. These data have established that up-regulation of Pak1 occurs in HCCs and is associated with a metastatic phenotype.



Figure 3. siRNA knockdown of Pak1 inhibited HCC cell migration. *A, top,* Pak1 siRNA and control siRNA were transfected into HepG2 cells before performing the Transwell assay; *bottom,* quantification of three independent experiments. *Columns,* mean; *bars,* SD. **, $P < 0.001$, *t* test. *Inset,* Western blotting result of Pak1 protein of HepG2 cells transfected with Pak1 siRNA and control siRNA. *B,* the expression plasmids of GFP alone, GFP-fusion form of WT (GFP-Pak1), and a dominant-inactive mutant of Pak1 (GFP-Pak1 K299R) were transfected into HepG2 cells with similar transfection efficiencies estimated by the green fluorescence (each transfection was close to 50%) for Transwell assays. Quantification of three independent experiments. *, $P < 0.05$, *t* test. *C,* mRNA and protein expression level of Pak1 in H2M and H2P. *D,* two Pak1 siRNAs and control siRNA, respectively, were transfected into H2M cells before performing the Transwell assay. *Columns,* mean of the Transwell assay results from three independent experiments; *bars,* SD. **, $P < 0.001$, *t* test, statistical significance between control and siPak1 and siPak1-2. *Inset,* Western blotting result of Pak1 protein of H2M cells transfected with Pak1 siRNA (siPak1 and siPak1-2) and control siRNA.

Downloaded from cancerres.aacrjournals.org on December 5, 2020. © 2007 American Association for Cancer Research.



Figure 4. Pak1 overexpression did not affect HCC cell proliferation rate. The proliferation rates of the EGFP control (□) and Pak1 stable clones WT-5 (▲), and WT-7 (♦) were determined as described in Materials and Methods. *Inset,* Western blotting analysis of the expression of cyclin D and β-actin in these clones stably expressing Pak1 (WT-5 and WT-7) and the EGFP control (GFP).

We have shown that *Pak1* was overexpressed at both mRNA and protein levels in our human HCC samples. The mechanism of this overexpression is currently unclear, but it has been reported that chromosome region 11q13-14, which contains the *Pak1* gene, is frequently amplified in HCCs (19). The possibility that the enhanced Pak1 expression is due to aberration in promoter activity and/or protein turnover cannot be completely ruled out. In this study, we have documented that not only was the Pak1 overexpressed, the Pak1 activity was also increased in HCCs, as revealed by the phosphospecific antibody that recognizes the activated form of Pak1.

Several lines of evidence here have implicated that overexpression and activation of Pak1 is causally associated with HCC metastasis through the stimulation of cell mobility. First, we have shown that overexpression of Pak1 in human HCCs was associated with a more metastatic phenotype and a shorter disease-free survival. Second, the expression of *Pak1* at both mRNA and protein levels was significantly higher in H2M cells derived from a metastatic HCC than in H2P cells derived from the corresponding primary human HCC. Third, HCC cell lines stably expressing Pak1 had higher migration rate, whereas those with knockdown of endogenous Pak1 using siRNA had significantly reduced cell migration rates.

To investigate the underlying mechanism, we have shown that the ability of HCC cells to form stress fibers was attenuated by overexpression of Pak1. Furthermore, inhibition of JNK abolished Pak1-induced cell migration in HCC cells. Recently, it has been shown that phosphorylation of paxillin at serine residue 178 by JNK promotes cell migration (18). In this study, we showed that JNK was phosphorylated and activated in both clinical samples and HCC cell lines stably expressing Pak1. Moreover, we showed that paxillin phosphorylation at S178 by JNK was important for Pak1-mediated migration of HCC cells. Consistent with this notion, we also noticed that the basal phosphorylation level of S178 paxillin in H2M cells was high (Fig. 6*B, lanes 1* and *2*) and correlated with the highly metastatic property of the cells. With immunohistochemical staining, there was a substantial increase in the S178-phosphorylated paxillin in Pak1-overexpressing human HCCs. Although paxillin is phosphorylated by other kinases [e.g., focal adhesion kinase (20) and ERK (21)], JNK is the only kinase having been reported to phosphorylate paxillin at S178. The possibility that paxillin S178 is the target of other kinases is currently under investigation, but our data have



Figure 5. Activation of Pak1 and JNK in human HCCs. Semiquantitative RT-PCR results of Pak1 and Western blotting results of Pak1, phospho-Pak1 (*p-Pak1*), Rac1, Cdc42, ERK1/2, phospho-ERK (*p-ERK*) 1/2, JNK, phospho-JNK (*p-JNK*), and β-actin between selected tumor and nontumorous livers. *B,* Transwell assay was done with Pak1 stable clones (WT-5 and WT-7) and EGFP control in the presence or absence of SP600125 at 50 μmol/L. *C,* H2M cells were pretreated with pharmacologic inhibitors SP600125 (50 μmol/L; JNK inhibitor), U0126 (10 μmol/L; MEK inhibitor), and SB203580 (2.5 μmol/L; p38 MAPK inhibitor), respectively, before performing the Transwell assay. *Columns,* mean of three independent experiments; *bars,* SD. **, $P < 0.001$, *t* test, statistical significance between the DMSO control and SP600125.

Downloaded from cancerres.aacrjournals.org on December 5, 2020. © 2007 American Association for Cancer Research.



Figure 6. Pak1-mediated HCC migration required phosphorylation of paxillin at S178. *A,* H2M cells were serum starved and treated with HGF (40 ng/mL) for 0, 10, and 20 min. The cells were harvested and the immunoblot was probed with indicated antibodies. *B, left,* H2M cells were serum starved and treated with HGF (40 ng/mL; for 10 min). Alternatively, H2M cells were pretreated with JNK inhibitor SP600125 for 2 h followed by treatment of HGF or transfected with Pak1 siRNA. Western blotting was done using indicated antibodies. *Right,* quantification of at least three independent experiments. *Columns,* mean of relative S178 paxillin phosphorylation; *bars,* SD. *C,* representative immunohistochemical staining of anti–phospho-S178 paxillin antibody in an HCC with Pak1 overexpression and in corresponding nontumorous samples.

established the first evidence that paxillin S178 phosphorylation is associated with metastasis of HCC.

It has been reported that the main upstream regulators of Pak1 (i.e., Rac1 and Cdc42) are up-regulated in breast cancer (22). To address the issue of Pak1 activation in HCCs, we have examined the expression of Rac1 and Cdc42 in clinical samples but observed no significant difference of these regulators at protein level. Although the best evidence is to examine the activity state of these small G-proteins by GTP loading activity pull-down assay, it is still a technical challenge to use clinical samples for this assay. Pak1 has been reported to be activated via several other Cdc42/Rac1–independent mechanisms, such as interaction with lipid/sphingosine (23), filamin A (24), and adaptor protein Nck (25) and activation of phosphatidylinositol 3-kinase/Akt (26) and heterotrimeric G-protein (27). Particularly, we have observed that, with immunohistochemical analysis, some of the Pak1-overexpressing human HCCs displayed intense membranous staining, implying that Pak1 can be targeted to plasma membrane for activation in HCC. Consistent with this finding, we observed that the overexpressed EGFP-Pak1 protein in Pak1-stable cell line also localized mainly in cytoplasm and plasma membrane, as different from the EGFP control, in which GFP was present in both nucleus and cytoplasm (Supplementary Fig. S2). Thus, we would like to propose that the cytoplasmic accumulation of Pak1 due to gene overexpression may enhance the translocation of Pak1 onto the plasma membrane, leading to the activation of Pak1 as well as the increase in cell migration.

In this study, we observed little difference in the cell proliferation rates between cells stably expressing Pak1 and the parental cells. Although Pak1 has been shown to promote proliferation of breast cancer cells (17), it is possible that Pak1 will have different roles in the development of HCC. In fact, consistent with our *in vitro* finding in HCC cell lines, Pak1 overexpression was not associated with tumor size in our human HCCs. Thus far, our findings implicate that the major role of Pak1 in HCC is to promote cell migration.

In conclusion, we have shown that Pak1 is overexpressed in human HCCs and HCC cell lines and that Pak1 overexpression plays an important role in cancer metastasis. The mechanism by which Pak1 induces cancer metastasis may involve activation of JNK and phosphorylation of paxillin.

Acknowledgments

Received 1/30/2006; revised 2/26/2007; accepted 2/9/2007.

Grant support: Hong Kong Research Grants Council Projects HKU 7311/04M and HKU 7497/05M. D-Y. Jin is a Leukemia and Lymphoma Society Scholar.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. Gary Bokoch for providing the Pak1 plasmids, Dr. Chun-Ming Wong for assistance in statistical analysis of data, and Abel Chun for critical reading of the manuscript.

References

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37 Suppl 8:S4–66.
2. Bagrodia S, Cerione RA. Pak to the future. Trends Cell Biol 1999;9:350–5.
3. Bokoch GM. Biology of the p21-activated kinases. Annu Rev Biochem 2003;72:743–81.
4. Bekri S, Adelaide J, Merscher S, et al. Detailed map of a region commonly amplified at 11q13→q14 in human breast carcinoma. Cytogenet Cell Genet 1997;79:125–31.
5. Carter JH, Douglass LE, Deddens JA, et al. Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res 2004;10:3448–56.
6. Vadlamudi RK, Adam L, Wang RA, et al. Regulatable expression of p21-activated kinase-1 promotes anchorage-independent growth and abnormal organization of mitotic spindles in human epithelial breast cancer cells. J Biol Chem 2000;275:36238–44.

Downloaded from cancerres.aacrjournals.org on December 5, 2020. © 2007 American Association for Cancer Research.

7. Adam L, Vadlamudi R, Mandal M, Chernoff J, Kumar R. Regulation of microfilament reorganization and invasiveness of breast cancer cells by kinase dead p21-activated kinase-1. J Biol Chem 2000;275:12041–50.
8. Kumar R, Gururaj AE, Barnes CJ. p21-activated kinases in cancer. Nat Rev Cancer 2006;6:459–71.
9. Schurmann A, Mooney AF, Sanders LC, et al. p21-activated kinase 1 phosphorylates the death agonist bad and protects cells from apoptosis. Mol Cell Biol 2000;20:453–61.
10. Frost JA, Swantek JL, Stippec S, Yin MJ, Gaynor R, Cobb MH. Stimulation of NFκB activity by multiple signaling pathways requires PAK1. J Biol Chem 2000;275:19693–9.
11. Tang Y, Chen Z, Ambrose D, et al. Kinase-deficient Pak1 mutants inhibit Ras transformation of Rat-1 fibroblasts. Mol Cell Biol 1997;17:4454–64.
12. Bagheri-Yarmand R, Vadlamudi RK, Wang RA, Mendelsohn J, Kumar R. Vascular endothelial growth factor up-regulation via p21-activated kinase-1 signaling regulates heregulin-β1-mediated angiogenesis. J Biol Chem 2000;275:39451–7.
13. Hu L, Lau SH, Tzang CH, et al. Association of Vimentin overexpression and hepatocellular carcinoma metastasis. Oncogene 2004;23:298–302.
14. Leung TH, Ching YP, Yam JW, et al. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. Proc Natl Acad Sci U S A 2005;102:15207–12.
15. Ng IO, Poon RT, Lee JM, Fan ST, Ng M, Tso WK. Microvessel density, vascular endothelial growth factor, and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J Clin Pathol 2001;116:838–45.
16. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462–503.
17. Balasenthil S, Sahin AA, Barnes CJ, et al. p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells. J Biol Chem 2004;279:1422–8.
18. Huang C, Rajfur Z, Borchers C, Schaller MD, Jacobson K. JNK phosphorylates paxillin and regulates cell migration. Nature 2003;424:219–23.
19. Kusano N, Okita K, Shirahashi H, et al. Chromosomal imbalances detected by comparative genomic hybridization are associated with outcome of patients with hepatocellular carcinoma. Cancer 2002;94:746–51.
20. Romanova LY, Hashimoto S, Chay KO, Blagosklonny MV, Sabe H, Mushinski JF. Phosphorylation of paxillin tyrosines 31 and 118 controls polarization and motility of lymphoid cells and is PMA-sensitive. J Cell Sci 2004;117:3759–68.
21. Ishibe S, Joly D, Liu ZX, Cantley LG. Paxillin serves as an ERK-regulated scaffold for coordinating FAK and Rac activation in epithelial morphogenesis. Mol Cell 2004;16:257–67.
22. Fritz G, Just I, Kaina B. Rho GTPases are over-expressed in human tumors. Int J Cancer 1999;81:682–7.
23. Bokoch GM, Reilly AM, Daniels RH, et al. A GTPase-independent mechanism of p21-activated kinase activation. Regulation by sphingosine and other biologically active lipids. J Biol Chem 1998;273:8137–44.
24. Vadlamudi RK, Li F, Adam L, et al. Filamin is essential in actin cytoskeletal assembly mediated by p21-activated kinase 1. Nat Cell Biol 2002;4:681–90.
25. Bokoch GM, Wang Y, Bohl BP, Sells MA, Quilliam LA, Knaus UG. Interaction of the Nck adapter protein with p21-activated kinase (PAK1). J Biol Chem 1996;271:25746–9.
26. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R. Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 1998;273:28238–46.
27. Lian JP, Crossley L, Zhan Q, et al. Antagonists of calcium fluxes and calmodulin block activation of the p21-activated protein kinases in neutrophils. J Immunol 2001;166:2643–50.

Downloaded from cancerres.aacrjournals.org on December 5, 2020. © 2007 American Association for Cancer Research.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

American Association for Cancer Research

P21-Activated Protein Kinase Is Overexpressed in Hepatocellular Carcinoma and Enhances Cancer Metastasis Involving c-Jun NH_2-Terminal Kinase Activation and Paxillin Phosphorylation

Yick-Pang Ching, Veronica Y.L. Leong, Man-Fong Lee, et al.

Cancer Res 2007;67:3601-3608.

Updated version	Access the most recent version of this article at: http://cancerres.aacrjournals.org/content/67/8/3601
Supplementary Material	Access the most recent supplemental material at: http://cancerres.aacrjournals.org/content/suppl/2007/04/12/67.8.3601.DC1

Cited articles	This article cites 27 articles, 14 of which you can access for free at: http://cancerres.aacrjournals.org/content/67/8/3601.full#ref-list-1
Citing articles	This article has been cited by 15 HighWire-hosted articles. Access the articles at: http://cancerres.aacrjournals.org/content/67/8/3601.full#related-urls

E-mail alerts	Sign up to receive free email-alerts related to this article or journal.
Reprints and Subscriptions	To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.
Permissions	To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/67/8/3601. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.

Downloaded from cancerres.aacrjournals.org on December 5, 2020. © 2007 American Association for Cancer Research.